MetrumRG ACoP Schedule

    Workshop | Podium Presentations | Research Posters

    Workshop & Podium Presentations

    Workshop:
    Efficient reproducible Bayesian population PK modeling with NONMEM and Stan/Torsten.
    This 2-day workshop provides a guided hands-on experience in performing efficient reproducible and traceable Bayesian PPK analyses. We will walk through both NONMEM-based and Stan-based workflows. Such workflows are facilitated by the use of MeRGE (Metrum Research Group Ecosystem) open-source tools that have been extended to support fully Bayesian analyses with either NONMEM or Stan.

    Presenters: William Gillespie, Ph.D.; Timothy Waterhouse, Ph.D.; Curtis Johnston, Pharm.D.; Seth Green, M.S.

    8:00 AM - 5:00 PM MST
    Location: Mesquite

     

    Quantitative clinical pharmacology of antibody conjugate development: challenges and opportunities.
    - Mechanistic QSP modeling for deeper understanding of ADC toxicities and combination effects with immunotherapies.
    Co-Speaker: Katharina Wilkins, Ph.D.
    1:45 - 2:15 PM MST

    The Practical Bayesian: How Bayesian Methodology is Incorporated into Clinical Drug Development.
    - Hybrid Approaches in Pharmacometric Modeling: Integrating Maximum Likelihood and Bayesian Estimation
    Speaker: Tim Waterhouse, Ph.D.
    1:45 PM - 2:15 PM MST

    BoF Session:
    Pharmacometrics limited by the industry?
    Co-Chair: Stacey Tannenbaum, Ph.D., FISoP
    1:45 PM - 3:15 PM MST

    Research Posters

    Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin.
    Jia Kang, Ph.D.; Matthew Wiens, M.A.; James Rogers, Ph.D.; Kyle Baron, Pharm.D., Ph.D. #M-052

    Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic.
    Marc R. Gastonguay, Ph.D.; Dan Polhamus, Ph.D. Michelle Johnson, M.B.A.; Eric Anderson, M.S.; Kyle Barrett. #M-036

     

    How to Make a Salad? Rethinking Pharmacometric/QSP Model Composition using Open-Source Julia Tools.
    Ahmed Elmokadem, Ph.D.; Ellen Swanson, Ph.D.; Jimena Davis, Ph.D.; Timothy Knab, Ph.D.; Daniel Kirouac, Ph.D. #T-040

    Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined with Mosunetuzumab and  Glofitamab Helps Guide Dosing for Patients with DLBCL.
    Yuezhe Li, Ph.D.; Katharina Wilkins, Ph.D.; Tim Knab, Ph.D.; Daniel Kirouac, Ph.D. #T-077

    Symbolic PBPK-PDE Modeling using Open-Source Julia Tools.
     Ahmed Elmokadem, Jimena Davis, Yuezhe Li, Timothy Knab, and Daniel Kirouac. #T-039

    The Effect of CYP2B6 Genotype on the Clearance and Autoinduction of Efavirenz in Healthy Subjects and the Subsequent Impact on Efavirenz Exposure.
     Mike Heathman, M.S. #T-054

    Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections.
    Rena Byrne, Ph.D.; Hillary Husband, Ph.D.; Megan Cala Pane, Ph.D.; Curtis Johnston, Pharm.D. #W-011

    Gompertz Cure Rate Survival Models with Stan and brms.
    Todd Yoder, Ph.D.; Andrew Tredennick, Ph.D.; Timothy Waterhouse, Ph.D. #W-136

    Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis.
    Timothy Waterhouse, Ph.D.; Mike Heathman M.S. (contributing). #W-032

    Losing the Forest: Causal Shapley Values for interpretation of Population-Pharmacometric Models.
    Matthew Wiens, M.S.; Elias Clark, Ph.D.; Curtis Johnston, Pharm.D. #W-133

    pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling.
     Grace O’Brien, Ph.D.; Eric Anderson, Ph.D.; Michael McDermott,  Ph.D.; Kyle Barrett, Kyle T. Baron, Pharm.D., Ph.D.; Timothy Waterhouse, Ph.D.; Seth Green, M.S.; Katherine Kay, Ph.D. #W-088

    Population Pharmacokinetic and Exposure-Response Modeling Analyses to Support Valemetostat Dose Recommendations in relapsed/refractory (R/R) Peripheral T-cell Lymphoma (PTCL) patients.
    Hiroyuki Inoue et al with co-author contributions from Ramon Garcia, Ph.D. #W-046

    Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients
    Daisuke Takaichi et al with co-author contributions from Kiersten Utsey, Ph.D.; Matthew Riggs, Ph.D., FISoP. #W-120

    Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions.
    Annaliese Wieler, M.S.; Matthew Wiens, M.A.; Samuel P. Callisto, Ph.D.; Megan Cala Pane, Ph.D.; Hillary Husband, Ph.D. #W012

    Scientific Project Management (SPM) to Enhance Model-Informed Drug Development.
    Jeannine Fisher, M.S.; William Knebel Pharm.D, Ph.D; Matthew Riggs, FISoP, Ph.D; Bryon Baxter; Uchenna Emechebe, Ph.D; Joseph Pliss, M.B.A.  #W031

    Simulating Dynamic Adaptive Dosing Regimens from PK and PKPD Models Using mrgsolve
    Kyle Baron, Pharm.D., Ph.D. #W-007